Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Enzalutamide
Brand: Xtandi 40mg
Manufacturer /
TM Owner
Astellas Pharma
Origin: Japan

Xtandi 40mg Capsule

Xtandi delivers Enzalutamide as a hormonal cancer therapy. It suppresses or blocks the hormones that fuel hormone-sensitive cancers, slowing disease progression. It is used in the treatment of men's health conditions. It is supplied as a capsule (40mg). Its targeted profile makes it a valued choice in contemporary clinical practice.
Strength: 40mg
Pack Size: 120s
Storage: 20°C to 25°C
Form: Capsule

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Xtandi 40 mg capsules contain enzalutamide, an androgen receptor inhibitor taken by mouth for prostate cancer.
  • In the US, Xtandi is indicated for castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk of metastasis; the EU label also covers high-risk non-metastatic castration-resistant disease and metastatic castration-resistant disease before and after docetaxel chemotherapy, among other stages, in adult men.
  • The recommended dose is 160 mg once daily, taken as four 40 mg capsules, with or without food.
  • Xtandi is also supplied as 40 mg and 80 mg tablets, and the capsule pack in this listing is the 40 mg capsule (120 capsules).
  • It is marketed by Astellas Pharma US and Pfizer, and you take it yourself at home under specialist supervision.

Side Effects

  • The most common reactions (10% or more and at least 2% more often than placebo) are musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhoea, high blood pressure, bleeding (haemorrhage), falls, fractures and headache.
  • Serious effects need urgent attention: seizure (about 0.6% overall and 2.2% in people with predisposing factors), posterior reversible encephalopathy syndrome (PRES) with headache, confusion or vision changes, hypersensitivity reactions, ischaemic heart disease, falls and fractures, and dysphagia or choking.
  • The EU label also lists second primary malignancies and severe skin reactions.
  • The label carries no boxed warning.
  • Seek urgent help for a seizure, chest pain, an allergic reaction or sudden confusion, and tell your team about falls or bone pain.

Precautions & Warnings

  • Xtandi can cause seizures, so tell your healthcare provider about any history of seizures, brain injury, stroke or medicines that lower the seizure threshold, and ask about activities such as driving or swimming.
  • Report signs of PRES, allergic reactions, heart disease symptoms, falls and difficulty swallowing.
  • Xtandi can cause fetal harm and loss of pregnancy; men with female partners who could become pregnant should use effective contraception (in the EU, a condom) during treatment and for 3 months after the last dose.
  • In the EU it is contraindicated in women who are or may become pregnant.
  • Reproductive toxicity data suggest it may affect male fertility.
  • Xtandi can interfere with digoxin immunoassays.
  • Swallow the capsules whole with water: do not chew, dissolve, open, cut or crush them.
  • Store at 20°C to 25°C in a dry place with the container tightly closed.

Avoid Interactions

  • Medicines that increase exposure: strong CYP2C8 inhibitors should be avoided, or the Xtandi dose reduced to 80 mg daily if co-administration cannot be avoided.
  • Medicines that reduce efficacy: strong CYP3A4 inducers should be avoided, or the Xtandi dose increased to 240 mg daily if unavoidable.
  • Xtandi is itself a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer, so it can lower the levels and effect of many other medicines that depend on those enzymes; your prescriber or pharmacist will review your other medicines.
  • Xtandi can also interfere with digoxin immunoassays.
  • Tell your healthcare provider about all prescription medicines, over-the-counter products and herbal supplements before starting or changing any treatment.

References

Frequently Asked Questions

Xtandi (enzalutamide) is a prostate cancer medicine for adult men. In the US it treats castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. The EU label also covers other prostate cancer stages.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.